We are live on ! Find out more
GP

Girard Partners Portfolio holdings

AUM $1.06B
1-Year Est. Return 17.26%
This Fund
S&P 500
This Quarter Est. Return
+6.74%
1 Year Est. Return
+17.26%
3 Year Est. Return
+25.75%
5 Year Est. Return
+90.99%
10 Year Est. Return
+213.34%
AUM
$947M
AUM Growth
+$42.3M
Cap. Flow
-$10.1M
Cap. Flow %
-1.07%
Top 10 Hldgs %
37.5%
Holding
265
New
13
Increased
83
Reduced
137
Closed
13

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$5.48M
2
DHI icon
D.R. Horton
DHI
+$4.76M
3
CSCO icon
Cisco
CSCO
+$4.46M
4
STZ icon
Constellation Brands
STZ
+$4.2M
5
DGX icon
Quest Diagnostics
DGX
+$1.8M

Sector Composition

Rank Sector Weight
1 Technology 21.18%
2 Healthcare 10.11%
3 Financials 8.69%
4 Consumer Discretionary 6.97%
5 Industrials 5.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDT icon
101
Medtronic
MDT
$108B
$1.83M 0.19%
20,731
+1,630
+9% +$140K
VOE icon
102
Vanguard Mid-Cap Value ETF
VOE
$23.8B
$1.81M 0.19%
13,050
-1,004
-7% -$134K
SPY icon
103
State Street SPDR S&P 500 ETF Trust
SPY
$781B
$1.8M 0.19%
4,053
-20
-0.5% -$8.39K
CME icon
104
CME Group
CME
$92.3B
$1.73M 0.18%
9,324
+425
+5% +$78.5K
UPS icon
105
United Parcel Service
UPS
$96B
$1.72M 0.18%
9,620
-9,885
-51% -$1.76M
ADSK icon
106
Autodesk
ADSK
$47.7B
$1.72M 0.18%
8,418
+781
+10% +$156K
VZ icon
107
Verizon
VZ
$198B
$1.72M 0.18%
46,169
-3,246
-7% -$120K
CIEN icon
108
Ciena
CIEN
$53.4B
$1.7M 0.18%
40,036
-6,089
-13% -$277K
XOM icon
109
ExxonMobil
XOM
$642B
$1.67M 0.18%
15,610
-646
-4% -$70.5K
SPDW icon
110
State Street SPDR Portfolio Developed World ex-US ETF
SPDW
$39.8B
$1.66M 0.18%
50,921
+4,155
+9% +$136K
DFAC icon
111
Dimensional US Core Equity 2 ETF
DFAC
$47.6B
$1.64M 0.17%
+60,377
New +$1.56M
VTEB icon
112
Vanguard Tax-Exempt Bond Index Fund
VTEB
$45.2B
$1.63M 0.17%
32,536
-30,670
-49% -$1.54M
MET icon
113
MetLife
MET
$61.2B
$1.61M 0.17%
28,398
+3,288
+13% +$182K
WSO icon
114
Watsco Inc
WSO
$15B
$1.56M 0.16%
+4,084
New +$1.38M
MBB icon
115
iShares MBS ETF
MBB
$39.1B
$1.54M 0.16%
16,488
+227
+1% +$21.4K
FLO icon
116
Flowers Foods
FLO
$1.62B
$1.54M 0.16%
61,788
+6,089
+11% +$161K
DOX icon
117
Amdocs
DOX
$5.64B
$1.45M 0.15%
14,709
-374
-2% -$35.2K
APD icon
118
Air Products & Chemicals
APD
$65.2B
$1.44M 0.15%
4,808
+162
+3% +$46.1K
IDXX icon
119
Idexx Laboratories
IDXX
$43.9B
$1.43M 0.15%
2,844
-3
-0.1% -$1.44K
PLD icon
120
Prologis
PLD
$137B
$1.42M 0.15%
11,587
+4,017
+53% +$494K
FAST icon
121
Fastenal
FAST
$54.7B
$1.35M 0.14%
45,810
-3,234
-7% -$88.5K
SCZ icon
122
iShares MSCI EAFE Small-Cap ETF
SCZ
$13.3B
$1.33M 0.14%
22,604
+1,073
+5% +$64.2K
INCY icon
123
Incyte
INCY
$23.7B
$1.31M 0.14%
21,093
+4,955
+31% +$331K
ABBV icon
124
AbbVie
ABBV
$454B
$1.31M 0.14%
9,702
-1,818
-16% -$267K
VBR icon
125
Vanguard Small-Cap Value ETF
VBR
$37.3B
$1.28M 0.13%
7,715
-604
-7% -$95.1K

Similar funds

Girard Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Girard Partners held 265 positions worth $947M, up 4.7% from $904M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Girard Partners's Q2 2023 filing shows 13 new, 83 increased, 137 reduced and 13 closed positions. Its largest new stake was Charles River Laboratories: 20,680 shares worth $4.35M. The largest sale was Amgen, an estimated $5.48M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.

  • Girard Partners's largest Q2 2023 buy was Charles River Laboratories: 20,680 shares worth $4.35M.
  • Girard Partners added most to Estee Lauder in Q2 2023, an estimated $3.62M increase.
  • Girard Partners's biggest Q2 2023 reduction was Amgen, cutting an estimated $5.48M.
  • Girard Partners fully exited State Street Consumer Staples Select Sector SPDR ETF in Q2 2023, selling an estimated $608K.
  • Girard Partners's ten largest holdings make up 37% of its $947M portfolio in Q2 2023.
  • Girard Partners opened 13 new positions and closed 13 in Q2 2023.
  • Girard Partners's portfolio value rose 4.7% quarter-over-quarter to $947M.

Based on Girard Partners's 13F filing for Q2 2023, filed 15 Aug 2023.